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Abstract
Sufficient oxygen supply is crucial for the development
and physiology of mammalian cells and tissues. When
simple diffusion of oxygen becomes inadequate to pro-
vide the necessary flow of substrate, evolution has pro-
vided cells with tools to detect and respond to hypoxia
by upregulating the expression of specific genes, which
allows an adaptation to hypoxia-induced stress condi-
tions. The modulation of cell signaling by hypoxia is an
emerging area of research that provides insight into the
orchestration of cell adaptation to a changing environ-
ment. Cell signaling and adaptation processes are often
accompanied by rapid and/or chronic remodeling of
membrane lipids by activated lipases. This review high-
lights the bi-directional relation between hypoxia and
lipid signaling mechanisms.
Keywords: eicosanoids; gene expression; hypoxia;
hypoxia-inducible factor; signal transduction;
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Introduction
To ensure survival in changing environments, mammalian
cells have developed mechanisms to respond to reduced
oxygen availability (hypoxia) and to maintain energy bal-
ance. Hypoxia leads to diminished oxidative phospho-
rylation and to a depletion of cellular ATP. Ultimately,
chronic hypoxia can result in cell death.
Many physiological responses to hypoxia are molec-
ularly controlled by a family of transcription factors
denoted as hypoxia-inducible factors (HIF), which have
been proposed to be master regulators of oxygen
homeostasis. Under normoxia, HIF transcription factors
are subjected to a very rapid turnover, in that constitu-
tively synthesized HIF protein is rapidly degraded again
by the 26S proteasome pathway. Under hypoxic condi-
tions, HIF-1 is stabilized instantaneously, resulting in an
accumulation of HIF-1 protein that translocates into the
nucleus and binds to hypoxia-responsive elements
(HREs) in the promoter of hypoxia target genes to acti-
vate their expression. A multitude of genes have been
shown to be regulated by hypoxia. These mainly include
genes involved in energy metabolism, cell growth and
viability, vascular development and remodeling, erythro-
poiesis and iron metabolism (for a review, see Semenza,
1999, 2006). However, in pathological processes such as
tumor growth, wound healing, retinopathy, and ischemic
diseases, hypoxia has also evolved as an important
stimulus.
Oxygen-sensing mechanisms
When simple diffusion of oxygen becomes inadequate to
provide the necessary flow of substrate, evolution has
equipped cells with tools to register and respond to
hypoxia by upregulating the expression of specific genes,
which allows adaptation to hypoxia-induced stress con-
ditions caused by conditions including high altitude,
anemia and wound healing, or during development
(Semenza, 1999; Pugh and Ratcliffe, 2003). One of the
master regulators of these adaptational changes in gene
transcription is the HIF family of transcription factors. The
functional entity of these transcription factors consists of
a/b-heterodimers. HIF-1b, also denoted as the aryl
hydrocarbon receptor nuclear translocator (ARNT), is
constitutively expressed and, like the a-subunits of HIF,
is a member of the basic helix-loop-helix (bHLH)-PAS
family (Semenza, 1999, 2006; Pugh and Ratcliffe, 2003).
To date, three mammalian HIF a-subunits have been
identified, HIF-1a, HIF-2a (also known as EPAS) and HIF-
3a, which are all oxygen-sensitive components, but differ
in their tissue expressions. Whereas HIF-1a is ubiqui-
tously expressed, HIF-2a and -3a show a more restricted
expression pattern. HIF-2a is highly expressed in endo-
thelial cells (Elvert et al., 1999; Haase, 2006), but is also
found in renal interstitial fibroblast-like cells (Haase, 2006)
and renal mesangial cells (Petry et al., 2005). HIF-3a
exists as at least six splice variants, which can be detect-
ed as multiple RNA species in Northern blot analyses
with sizes of 1.5, 3.0, 7.0, and 7.5 kb (Maynard et al.,
2003). Strong expression of HIF-3a was observed in the
heart, placenta, and skeletal muscle, whereas a weak
expression profile was found in the lung, liver, and kidney
(Maynard et al., 2003). The functions of the different
HIF-a proteins in a hypoxic setting are still unclear. How-
ever, it has been speculated that HIF-3a, which lacks one
of the two transactivation domains present in the other
two HIF-a proteins, may serve as a negative regulator of
hypoxia-triggered gene transcription by competing for
HIF-1b binding (Hara et al., 2001).
Under ambient oxygen conditions, all three HIF-a sub-
types are continuously hydoxylated on critical proline
residues (Pro402 and/or 564 in HIF-1a) by prolyl hydroxylases
(PHD)-1, -2 or -3, and subsequently associate with the
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von-Hippel-Lindau (VHL) tumor suppressor protein,
which is a component of the E3 ubiquitin ligase complex
and directs HIF-a subtypes to degradation by the 26S
proteasome pathway (Maxwell et al., 1999; Epstein et al.,
2001). Importantly, hypoxia slows down the degradation
of HIF-1a, because the prolyl hydroxylases are oxygen-
dependent and non-hydroxylated HIF-1a is not recog-
nized by the VHL protein. As a result HIF-1a accumulates
and translocates into the nucleus, where it dimerizes with
HIF-1b to bind to HRE, an enhancer element containing
the consensus sequence 59-ACGTG-39, located in the
promoter regions of many hypoxia target genes, and acti-
vates their expression.
Besides proline hydroxylation, HIF-1a is also hydroxy-
lated on asparagine (Asp803 in HIF-1a) under normoxic
conditions by the factor inhibiting HIF-1 (FIH-1) (Mahon
et al., 2001; Peet and Linke, 2006) and this modification
prevents the interaction of HIF-1a with its co-activators
CREB-binding protein (CBP) and p300 (Dames et al.,
2002; Freedman et al., 2002). Under hypoxic conditions,
oxygen becomes rate-limiting for FIH-1 activity, resulting
in unhydroxylated HIF-1a at Asp803 and consequently
allowing association of HIF-1a with CBP and p300.
These co-activators act as a link to RNA polymerase II
and other factors within the initiation complex.
Physiological and pathophysiological aspects
of hypoxia
Hypoxia triggers both acute and chronic physiological
responses. Acute responses may occur as early as sec-
onds after exposure to low oxygen and involve the mod-
ulation of constitutively expressed proteins, including ion
channels. The first ion channels shown to be sensitive to
hypoxia were Kq channels in cells of the carotid body
(Lopez-Barneo et al., 1988, 1999). However, it now
seems that various Kq channels are differentially affected
by hypoxia (Hool, 2005). For example, in pulmonary
artery smooth muscle cells, particularly the Kv1.5 chan-
nel is inhibited by hypoxia, leading to membrane depo-
larization, influx of Ca2q through voltage-dependent
channels and myocyte contraction (Archer et al., 2004).
On the other hand, in systemic arteries and cerebral ves-
sels, hypoxia rather increases Kq currents, which causes
vasodilatation and leads to an increase in blood supply
to poorly perfused tissue. In renal arteries, hypoxia also
stimulates an increase in outward Kq current associated
with dilatation of the arteries (Michelakis et al., 2002).
In addition, various Ca2q channels are affected by
hypoxia. Although Ca2q channels may be indirectly
affected by hypoxia-altered Kq currents, it has now
become evident that Ca2qchannels are also directly influ-
enced by hypoxia (for a review see Lopez-Barneo et al.,
1999). In voltage-clamped arterial myocytes, hypoxia
selectively reduces the influx of Ca2q through voltage-
dependent L-type Ca2q channels (Franco-Obregon et al.,
1995; Fearon et al., 1997), whereas T-type Ca2qchannels
were unaltered by hypoxia (Franco-Obregon et al., 1995).
Chronic hypoxia-mediated cell responses require
hours and mainly involve gene expression leading to de
novo protein synthesis. It has become clear that HIF-1a
regulates a multitude of genes that are involved in phys-
iological adaptive processes. More than 70 genes have
been identified as being HIF-regulated, including genes
involved in energy metabolism, erythropoiesis, angio-
genesis, proliferation, cell survival and apoptosis (for
reviews see Semenza, 1999, 2006). However, HIF-medi-
ated gene transcription is not the only mechanism by
which hypoxia modulates cellular events. Thus, oxygen-
consuming enzyme reactions may also be affected by
hypoxia (see the section ‘hypoxia-inducible genes’).
Interestingly, HIF-1a is upregulated not only by hypox-
ia, but also under certain conditions during normoxia. In
this context, pro-inflammatory cytokines such as inter-
leukin-1b (IL-1b) and tumor necrosis factor a (TNFa)
have been shown to increase HIF-1a activity in normoxic
human hepatoma cells (Hellwig-Burgel et al., 1999),
human gingival and synovial fibroblasts (Thornton et al.,
2000), and even in experimental wounds during acute
inflammation (Albina et al., 2001).
Moreover, the gaseous molecule nitric oxide (NO)
exerts a dual role in the regulation of HIF-1a expression.
Whereas it induces HIF-1a expression under normoxic
conditions, it reduces HIF-1a expression under hypoxic
conditions (Sogawa et al., 1998). Mechanistically, it was
proposed that NO modulates the prolyl hydroxylase
activity and thereby alters HIF-1a accumulation (Metzen
et al., 2003; Callapina et al., 2005).
Additional factors that have been shown to induce HIF-
1a expression include insulin in HepG2 cells (Zelzer et al.,
1998; Stiehl et al., 2002) and L8 myoblasts (Zelzer et al.,
1998), thrombin in vascular smooth muscle cells (Go¨rlach
et al., 2001), angiotensin II in renal tubuloepithelial cells
(Sanchez-Lopez et al., 2005), and oxidized low-density
lipoprotein (oxLDL) in human macrophages (Shatrov et
al., 2003). For both angiotensin II and oxLDL, this was
shown to mechanistically involve the intermediate gen-
eration of reactive oxygen species (ROS) (Shatrov et al.,
2003; Sanchez-Lopez et al., 2005).
Finally, prostaglandins have evolved as important reg-
ulators of HIF-1 expression. In this context, Liu et al.
(2002) and Zhong et al. (2004) demonstrated that pros-
taglandin E2 (PGE2) specifically stabilizes HIF-1a expres-
sion in various tumor cells. Furthermore, overexpression
of cyclooxygenase-2 (COX-2) in gastric carcinoma cells
resulted in increased VEGF production and increased cell
proliferation and tube formation of HUVECs, an effect
that was abolished by HIF-1a antisense transfection
(Huang et al., 2005). In gastric microvascular endothelial
cells, hypoxia-triggered HIF-1a accumulation and angio-
genesis were reduced in the presence of non-steroidal
anti-inflammatory drugs (NSAIDs), which are classical
COX inhibitors. However, this effect was only partially
reversed by addition of prostaglandins, suggesting that
both prostaglandin-dependent and -independent mech-
anisms are involved (Jones et al., 2002). Similarly, the
highly selective COX-2 inhibitor NS398 also blocked
hypoxia-induced HIF-1a expression, an effect that was
detected in COX-2-expressing as well as COX-2-defi-
cient colon cancer cell lines (Zhong et al., 2004). More-
over, Palayoor et al. (2003) even demonstrated that the
NSAID-mediated reduction in HIF-1a occurred in a com-
pletely COX-2-independent way. All these partly conflict-
ing data show that prostaglandins do have an impact on
HIF-1a expression, although the mechanism involved
remains uncertain in particular settings.
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Remarkably, under disease conditions HIF-1a has also
evolved as an important transcription factor. Inflamed tis-
sues have lower levels of oxygen than healthy tissues.
This causes an accumulation of HIF-1a and helps to
establish a rapid and fully developed inflammatory
response. In this context, it is known that leukocytes, the
key players of the innate immune system, have adapted
to hypoxia and exhibit high degrees of lactate formation,
even under normoxic conditions. Moreover, tissue
hypoxia is a common feature in solid tumors and a driv-
ing force for tumor angiogenesis and progression.
The generation of homozygous HIF-1a-/- mice has
been attempted. However, the complete deficiency of
HIF-1a resulted in developmental arrest and death by
day 11 of embryogenesis, with manifestations of neural
tube defects, cardiovascular malformations, and marked
cell death within the cephalic mesenchyma (Iyer et al.,
1998). In a recent study, conditional knockouts of HIF-1a
have been generated (Cramer et al., 2003). It was shown
that HIF-1a is essential for myeloid cell infiltration and for
the regulation of glycolytic capacity of myeloid cells.
When HIF-1a was absent, the cellular ATP pool was
drastically reduced. The metabolic defect resulted in a
severe dysfunction of myeloid cell aggregation, motility,
invasiveness, and bacterial killing (Cramer et al., 2003).
Hypoxia-inducible genes
A multitude of hypoxia-regulated genes have been iden-
tified (for reviews see Semenza, 1999, 2006), including
genes involved in various aspects of energy metabolism,
such as glucose transporters, glycolytic and gluconeo-
genic enzymes, of iron metabolism including transferrin,
of catecholamine metabolism, such as tyrosine hydroxy-
lase, of vascular control, including nitric oxide synthases
and endothelin-1, and of angiogenesis, such as VEGF
and PDGF. Moreover, erythropoietin was described as
the prototypic HIF-regulated gene, which regulates eryth-
ropoiesis and thus, oxygen transport capacity.
Interestingly, there is a partial overlap between hypox-
ia-regulated genes and NO- and ROS-targeted genes
(Pfeilschifter et al., 2001). This may arise from the fact
that, as already outlined above, NO is able to upregulate
HIF-1a expression and in this sense mimics hypoxic con-
ditions. However, not all cellular events modulated by
hypoxia are exclusively explained by HIF-mediated gene
transcription. Oxygen-consuming enzyme reactions may
also be affected. Such reactions are very prominent in
lipid signaling cascades. For example, oxygen is a sub-
strate for cyclooxygenases, lipoxygenases and cyto-
chrome P450 enzymes, and therefore an effect of
hypoxia on these cascades is very obvious.
Lipid signaling
Signal transduction is an important event in cell-cell com-
munication and involves the action of second messen-
gers to transmit signals from the extracellular to the
intracellular space. Cyclic AMP and calcium are the two
main second messengers used by hormones for con-
trolling physiological cellular processes. However, during
the last decades, evidence has accumulated that points
to a key role for lipids in cell signaling. The milestone for
a central role of lipids in signal transduction was mani-
fested by the discovery of the phosphoinositide (PI) cycle
(Berridge, 1984). It was recognized that upon hydrolysis
of phosphatidylinositol 4,5-bisphosphate by phospho-
lipase C, two important second messengers are gener-
ated, the hydrophilic inositol 1,4,5-trisphosphate (IP3) and
the lipophilic 1,2-diacylglycerol (DAG). Whereas IP3 inter-
acts with an intracellular membrane receptor and leads
to the mobilization of Ca2q, DAG directly binds to and
activates protein kinase C (PKC) and thereby initiates
important downstream signal transduction cascades
(Nishizuka, 1995).
Additional bioactive lipids were identified that can act
as second messengers and intracellular modulators
(Serhan et al., 1996). These include: arachidonic acid and
lysophospholipids, generated by the action of phospho-
lipases A2 (PLA2); phosphatidic acid (PA), a reaction prod-
uct of phospholipase D; 1-O-alkyl-2-acetyl-sn-glycero-
3-phosphocholine, also known as platelet-activating fac-
tor (PAF); phosphatidylinositol 3,4,5-trisphosphate (PIP3)
produced by phosphatidylinositol 3-kinases; and the
sphingolipids ceramide and sphingosine 1-phosphate
(S1P).
Hypoxia and eicosanoids
Eicosanoids largely contribute to the cardinal symptoms
of inflammation. The rate-limiting step in the synthesis of
eicosanoids (including prostaglandins, leukotrienes and
thromboxane) is the availability of free arachidonic acid,
generated by the action of a PLA2, which constitutes a
superfamily of cytosolic and secreted enzymes (for
review see Six and Dennis, 1998; Balsinde et al., 2002).
High levels of secreted PLA2 (sPLA2) have been found in
serum and exudates from patients suffering from inflam-
matory diseases, such as rheumatoid arthritis and acute
pancreatitis, and trauma (Hara et al., 1989; Nevalainen et
al., 2000). In particular, in diseases such as rheumatoid
arthritis, atherosclerosis and glomerulonephritis, hypoxia
is a prevalent factor that impacts on the recruitment and
function of immune cells and other aspects of disease
progression (Cramer et al., 2003; Demasi et al., 2003).
For many years it has been known that hypoxia is able
to increase PGE2 formation, as exemplified in cultures of
renal mesangial cells (Jelkmann et al., 1985). It was
recently outlined that this hypoxia-triggered PGE2 syn-
thesis is due to a potentiation of inflammatory cytokine-
induced sPLA2 expression, secretion and activity by
hypoxia (Petry et al., 2005). Importantly, hypoxia was
unable to induce sPLA2 in the absence of an inflamma-
tory stimulus. In mechanistic terms, HIF-2a was identi-
fied as the responsible hypoxia-upregulated transcription
factor that binds to two identified HRE sites in the sPLA2
promoter sequence of rat mesangial cells (Petry et al.,
2005). Such a coordinated action of two signaling path-
ways seems to be a typical feature in sPLA2 induction;
IL-1b plus NO (Rupprecht et al., 1999) or IL-1b plus per-
oxisome proliferator activated receptor (PPAR) a agonists
(Scholz-Pedretti et al., 2002) showed similar additive or
synergistic effects on sPLA2 mRNA expression compared
to IL-1b alone.
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Figure 1 Overview of the effects of hypoxia on eicosanoid-
generating enzymes.
Abbreviations: AA, arachidonic acid; COX, cyclooxygenase;
cPLA2, cytosolic phospholipase A2; CYP, cytochrome P450;
DAG, 1,2-diacylglycerol; EET, epoxyeicosatrienoic acid; IP3, ino-
sitol trisphosphate; LOX, lipoxygenase; LT, leukotrienes; PA,
phosphatidic acid; PG, prostaglandins; PKC, protein kinase C;
PLC, phospholipase C; sPLA2, secreted phospholipase A2.
In line with these findings, it was reported that during
ischemia, endothelial cells also respond with increased
PLA2 activity, which was suggested to belong to the
group of secreted PLA2s, but was not further specified
(Michiels et al., 2002). Furthermore, an increased amount
of arachidonic acid is also liberated from neuroblastoma
cells (Petroni et al., 2002) and from cultures of rat hip-
pocampal slices (Arai et al., 2001) upon ischemic injury.
However, these PLA2 activities were attributed to cyto-
solic PLA2 rather than secreted PLA2 (Arai et al., 2001).
Especially in the neuronal system, the inflammatory
responses occurring upon ischemic injury may contribute
to neuronal degeneration and the clinical manifestation
of Alzheimer’s disease.
Hypoxia was also identified as a co-stimulus for induc-
tion of another pro-inflammatory enzyme, inducible NO
synthase (iNOS). Thus, in macrophages, hypoxia poten-
tiated interferon-g-induced iNOS expression without
showing an effect alone (Melillo et al., 1996).
Furthermore, hypoxia may also affect cyclooxyge-
nases, which are important enzymes in the generation of
prostaglandins. In this context, Chida and Voelkel (1996)
showed that exposure of isolated perfused rat lungs to
acute hypoxia was sufficient to induce COX-2 expres-
sion. In various other cell types, including endothelial
cells (Schmedtje et al., 1997), epithelial cells (Bonazzi et
al., 2000) and human neural cells (Bazan and Lukiw,
2002), hypoxia was also able to induce COX-2 expres-
sion or potentiate cytokine-induced COX-2 expression.
It is tempting to speculate that hypoxia may also affect
the more downstream enzymes such as PGE2 synthase
and prostacyclin synthase to consistently and coordi-
nately upregulate eicosanoid biosynthesis. This concert-
ed action of hypoxia on the eicosanoid-generating
cascade of enzymes (for an overview see Figure 1) could
explain the well-documented increase in prostaglandin
synthesis in conditions of limited oxygen availability in
brain, kidney and heart, as well as in cell culture of endo-
thelial and mesangial cells (Busse et al., 1984; Jelkmann
et al., 1985; Kurtz et al., 1985; Michiels et al., 2002).
Hypoxia and diacylglycerol
Diacylglycerol (DAG) is an important lipid second mes-
senger directly regulating protein kinase C activity, which,
in turn, is involved in the regulation of many cell
responses including gene expression (for reviews see
Mellor and Parker, 1998; Aschrafi et al., 2003). Recently,
it was shown that hypoxia is able to increase cellular
DAG levels in HeLa cells (Aragones et al., 2001) and 293
T-cells (Temes et al., 2004). This hypoxia-mediated
increase in DAG was abolished by the putative phospha-
tidylcholine-specific phospholipase C inhibitor D609,
thus suggesting that hypoxia activates this enzyme (Ara-
gones et al., 2001). However, since PKC inhibitors had
no effect on hypoxia-induced HIF expression, it was con-
cluded that DAG targets other than DAG-activated PKC
were involved in HIF accumulation. Since phosphatidic
acid levels are also increased upon hypoxia due to stim-
ulated DAG kinase activity (Aragones et al., 2001), it was
proposed that this pathway of DAG/PA generation may
rather contribute to HIF activation.
In contrast, other groups could show that hypoxia
indeed leads to translocation and activation of the two
PKC-a and -´ isoenzymes in neonatal rat ventricular
myocytes (Goldberg et al., 1997). The role of PKC in
ischemia-reperfusion is currently unclear owing to many
conflicting reports. On the one hand PKC may be
involved in cell survival signaling, and on the other hand
it may be involved in detrimental processes (for a review
see Bright and Mochly-Rosen, 2005). In this context, it
is worth mentioning that PKC-a and -´ are considered
to mediate, in a cell type-specific manner, cPLA2 acti-
vation and subsequent eicosanoid formation, which pro-
vides an additional amplification loop to the interaction
of hypoxia and PLA2/COX-2 isozymes described above
(Huwiler et al., 1991; Huwiler and Pfeilschifter, 1993).
Hypoxia and sphingolipids
The sphingolipids ceramide and S1P have been attrib-
uted central but opposing roles in the regulation of cell
growth and death. Whereas ceramide is an inducer of
apoptosis in many cell types, S1P rather acts as an anti-
apoptotic agent and promotes cell proliferation (for
reviews see Huwiler et al., 2000; Spiegel and Milstien,
2003). Since hypoxia is also connected to cell prolifera-
tion, it is tempting to speculate that sphingolipids can
serve as mediators of hypoxia-induced proliferation, or
may themselves be affected by changing oxygen avail-
ability (for an overview see Figure 2). Indeed, Yun and
Kester (2002) were able to show that in smooth muscle
cells, hypoxia-triggered cell proliferation is abolished in
the presence of a putative sphingosine kinase inhibitor.
In addition, hypoxia led to an increased cellular level of
S1P with a concomitant decrease in ceramide as a con-
sequence of hypoxia-inhibited sphingomyelinase activity
(Yun and Kester, 2002). In line with these findings, Ahmad
et al. (2006) reported that in pulmonary smooth muscle
cells, hypoxia upregulated sphingosine kinase mRNA
expression and was able to potentiate S1P-stimulated
mitogen-activated protein kinase activity. In contrast, it
was reported that in cultures of rat renal tubular epithelial
cells, 1 h of hypoxia with glucose deprivation induced a
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Figure 2 Schematic overview on the effects of hypoxia on sphingolipid metabolism.
Abbreviations: Cer-synthase, ceramide synthase; nSMase, neutral sphingomyelinase; sph, sphingosine; S1P, sphingosine 1-
phosphate.
significant increase in ceramide, which was further accel-
erated after 1 h of reoxygenation (Basnakian et al., 2005).
This effect occurred independent of sphingomyelinase
activity and was due to increased ceramide synthase
activity (Basnakian et al., 2005).
In various models of myocardial ischemia-reperfusion,
changes in ceramide levels have been reported. In this
context, hypoxia-reoxygenation of cardiac myocytes
induced rapid activation of a neutral sphingomyelinase
activity (Hernandez et al., 2000). Similarly, in vitro ische-
mia (oxygen/serum/glucose deprivation) led to a pro-
gressive accumulation of ceramide in cardiomyocytes
(Bielawska et al., 1997).
Mice that were subjected to 45 min of unilateral renal
ischemia showed an approximately 50% decrease in cor-
tical ceramide and sphingosine levels (Zager et al., 1997).
After reperfusion, sphingosine returned to normal levels,
whereas ceramide further increased to supranormal lev-
els (Zager et al., 1997).
In a rat heart model, application of ischemia with sub-
sequent reperfusion induced apoptosis of myocardial
cells, an event that was mimicked in vitro by C2 ceramide
(Bielawska et al., 1997). In vivo, the content of ceramide
in the ischemic area was significantly elevated, thus sug-
gesting that ceramide signaling may be involved in ische-
mia/reperfusion death of myocardial cells (Bielawska et
al., 1997; Cordis et al., 1998). Furthermore, chronic expo-
sure of rats for 8 weeks to 10% oxygen, which equals
the oxygen conditions at an altitude of 4000 m, led to a
marked increase in cardiac mass in both the left and right
ventricles. In the right ventricle, this was associated with
a reduction in ceramide content and a slight increase in
DAG content (El Alwani et al., 2005).
As ceramide is degraded to sphingosine and may be
further converted to S1P, an involvement of S1P in the
ischemic reaction could also be envisioned. Indeed, it
was recently shown that deficiency of the S1P1 receptor
subtype resulted in induced expression of HIF-1a and
VEGF in deficient mice limbs (Chae et al., 2004).
Another coupling of hypoxia to sphingolipids was
shown in skin-specific ARNT/HIF-1b-deficient mice.
These mice died shortly after birth due to severe dehy-
dration caused by water loss caused by a defective epi-
dermal barrier function (Takagi et al., 2003). Lipid analysis
of the skin revealed significant changes in the composi-
tion of ceramides. Whereas normal murine epidermis
ceramides contain 2-sphingenine and 4-hydroxysphin-
ganine, the deficient epidermis contained sphinganine
instead of 4-sphingenine and the amount of 4-hydroxy-
sphinganine was greatly decreased, thus suggesting a
deficiency of dihydroceramide desaturase activity in
ARNT/HIF-1b-deficient cells (Takagi et al., 2003).
Perspectives
The observations cited above provide the framework to
begin to understand the cross-communication between
two important signaling cascades that have become
fashionable again. The identification of HIF-1 as the mas-
ter regulator of oxygen homeostasis and more recently
of the PHDs as the critical oxygen-sensing devices has
promoted the return of this research area to the scientific
center stage. Similarly, the discovery of lipid-regulated
key signaling elements including cell membrane recep-
tors (e.g., the S1P receptor family, formerly denoted as
Edg receptors) and transcription factors (e.g., PPARs)
has shifted the scientific spotlight back to membrane
lipids. The vital elegance and elaborate mechanisms that
have evolved to regulate fundamental cell responses are
attracting the attention of basic scientists, as well as cli-
nicians, and promise to provide novel pharmacological
approaches for the treatment of human diseases. Further
research progress in this area will address the interface
between signal transduction and translational medicine;
these results are likely to be very exciting.
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